BioPharma Dive4h
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
BioPharma Dive4h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
BioPharma Dive4h
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
BioPharma Dive7h
Pfizer taps a former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...